Intra Cellular Therapies, Inc. ITCI
We take great care to ensure that the data presented and summarized in this overview for Intra-Cellular Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITCI
View all-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$834 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$676 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$424 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.08MShares$406 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$402 Million3.71% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.44MShares$322 Million4.06% of portfolio
-
Deep Track Capital, LP Greenwich, CT2MShares$264 Million7.36% of portfolio
-
State Street Corp Boston, MA1.87MShares$247 Million0.01% of portfolio
Latest Institutional Activity in ITCI
Top Purchases
Top Sells
About ITCI
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Transactions at ITCI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 02
2025
|
Eduardo Rene Salas |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,567
-100.0%
|
$206,844
$132.0 P/Share
|
|
Apr 02
2025
|
Michael Halstead President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,307
-100.0%
|
$2,812,524
$132.0 P/Share
|
|
Apr 02
2025
|
Rory B Riggs |
SELL
Sale (or disposition) back to the issuer
|
Direct |
131,512
-100.0%
|
$17,359,584
$132.0 P/Share
|
|
Apr 02
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,811
-100.0%
|
$6,971,052
$132.0 P/Share
|
|
Apr 02
2025
|
Robert L Van Nostrand |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,340
-100.0%
|
$1,496,880
$132.0 P/Share
|
|
Apr 02
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,913
-100.0%
|
$5,664,516
$132.0 P/Share
|
|
Apr 02
2025
|
Sharon Mates Chairman and CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
190,000
-100.0%
|
$25,080,000
$132.0 P/Share
|
|
Apr 02
2025
|
Sharon Mates Chairman and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
945,235
-100.0%
|
$124,771,020
$132.0 P/Share
|
|
Apr 02
2025
|
Joel S Marcus |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
$1,320,000
$132.0 P/Share
|
|
Apr 02
2025
|
Joel S Marcus |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,238
-100.0%
|
$6,367,416
$132.0 P/Share
|
|
Mar 26
2025
|
Sharon Mates Chairman and CEO |
BUY
Bona fide gift
|
Indirect |
190,000
+50.0%
|
-
|
|
Mar 26
2025
|
Sharon Mates Chairman and CEO |
SELL
Bona fide gift
|
Direct |
190,000
-16.74%
|
-
|
|
Mar 10
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,757
-14.99%
|
$492,167
$131.24 P/Share
|
|
Mar 10
2025
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+22.66%
|
-
|
|
Mar 10
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,116
-5.57%
|
$408,196
$131.24 P/Share
|
|
Mar 10
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+11.61%
|
-
|
|
Mar 10
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,129
-0.88%
|
$1,326,899
$131.24 P/Share
|
|
Mar 10
2025
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,566
+1.76%
|
-
|
|
Mar 10
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,116
-6.77%
|
$408,196
$131.24 P/Share
|
|
Mar 10
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+13.76%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 691K shares |
|---|---|
| Grant, award, or other acquisition | 64.7K shares |
| Bona fide gift | 190K shares |
| Sale (or disposition) back to the issuer | 1.45M shares |
|---|---|
| Open market or private sale | 474K shares |
| Payment of exercise price or tax liability | 119K shares |
| Bona fide gift | 190K shares |